£20m to Push Failed Drugs with no Talk of Prevention

But this is not true. The Oxford University trial of homocysteineHomocysteine is an amino acid found in the blood. Elevated levels of homocysteine have been associated with narrowing and hardening of the arteries, an increased… lowering B vitamins, especially in those with sufficient omega-3 status, confirmed by other studies, showed three times the clinical benefit, with up to 73% reduced rate of brain shrinkage, compared to Donanemab, which increase the rate of brain shrinkage.

Several people died in the anti-amyloid trials, with over a quarter getting brain bleeding and swelling. Professor Paul Morgan, of the UK Dementia Research Institute Cardiff, described these drugs as “eye-wateringly expensive, difficult to administer and potentially harmful”. Is it really ethical to keep going down the defunct and dangerous anti-amyloid drug pathway?

We badly need a robust trial of the combination of homocysteine lowering B vitamins and omega-3 fish oils. Leading UK neurologists have been trying to get the £3 million needed to run such a definitive prevention trial – but MRC aren’t interested. ARUK allocate less than 5% of funds raised for non-drug prevention.

If you’d like to help make dementia prevention a reality become a Friend of foodforthebrain.org and write to your MP because it is tax payers money that is being spent pushing failed drug treatments.